Back to Search Start Over

Inhibition of G protein-coupled receptor 68 using homoharringtonine attenuates chronic kidney disease-associated cardiac impairment.

Authors :
Yoshida Y
Fukuoka K
Sakugawa M
Kurogi M
Hamamura K
Hamasaki K
Tsurusaki F
Sotono K
Nishi T
Fukuda T
Kumamoto T
Oyama K
Ogino T
Tsuruta A
Mayanagi K
Yamashita T
Fuchino H
Kawahara N
Yoshimatsu K
Kawakami H
Koyanagi S
Matsunaga N
Ohdo S
Source :
Translational research : the journal of laboratory and clinical medicine [Transl Res] 2024 Jul; Vol. 269, pp. 31-46. Date of Electronic Publication: 2024 Feb 23.
Publication Year :
2024

Abstract

Chronic kidney disease (CKD) induces cardiac inflammation and fibrosis and reduces survival. We previously demonstrated that G protein-coupled receptor 68 (GPR68) promotes cardiac inflammation and fibrosis in mice with 5/6 nephrectomy (5/6Nx) and patients with CKD. However, no method of GPR68 inhibition has been found that has potential for therapeutic application. Here, we report that Cephalotaxus harringtonia var. nana extract and homoharringtonine ameliorate cardiac inflammation and fibrosis under CKD by suppressing GPR68 function. Reagents that inhibit the function of GPR68 were explored by high-throughput screening using a medicinal plant extract library (8,008 species), and we identified an extract from Cephalotaxus harringtonia var. nana as a GPR68 inhibitor that suppresses inflammatory cytokine production in a GPR68 expression-dependent manner. Consumption of the extract inhibited inflammatory cytokine expression and cardiac fibrosis and improved the decreased survival attributable to 5/6Nx. Additionally, homoharringtonine, a cephalotaxane compound characteristic of C. harringtonia, inhibited inflammatory cytokine production. Homoharringtonine administration in drinking water alleviated cardiac fibrosis and improved heart failure and survival in 5/6Nx mice. A previously unknown effect of C. harringtonia extract and homoharringtonine was revealed in which GPR68-dependent inflammation and cardiac dysfunction were suppressed. Utilizing these compounds could represent a new strategy for treating GPR68-associated diseases, including CKD.<br />Competing Interests: Declaration of competing interest All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All the authors have read and approved the submission for publication.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1878-1810
Volume :
269
Database :
MEDLINE
Journal :
Translational research : the journal of laboratory and clinical medicine
Publication Type :
Academic Journal
Accession number :
38401836
Full Text :
https://doi.org/10.1016/j.trsl.2024.02.004